secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-08-03T11:15:25+00:00
Accession:  0001493152-26-035743
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma raises $5M from OPKO Health; norovirus Phase 1b data expected Q4 2026
--------------------------------------------------------------------------------

- Sold 5,474,053 shares to OPKO at $0.9134/share, gross proceeds $5.0M, no warrants.
- Proceeds to fund preclinical/clinical programs, including norovirus Phase 1b trial with topline data by end of Q4 2026.
- Dr. Phillip Frost, Chairman/CEO of OPKO, is co-founder, director, and principal stockholder of Cocrystal.
- Private placement under Section 4(a)(2) and Regulation D; shares unregistered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/0001493152-26-035743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer